Durvalumab 50 MG/ML

DRUG4 trials

Sponsors

Baki Topal, University of Cologne, University of Nebraska, Alliance Foundation Trials, LLC.

Conditions

Carcinoma, Non-Small Cell LungEsophageal AdenocarcinomaLung CancerPancreatic Cancer Non-resectableSmall Cell Lung Cancer (SCLC)

Phase 1

Safety & Efficacy of Consolidative Hypofractionated Radiation Therapy for Boosting Residual Lung Cancer With Durvalumab

TerminatedNCT04748419

University of NebraskaCarcinoma, Non-Small Cell Lung, Lung Cancer

Start: 2021-07-15End: 2025-09-26Updated: 2026-06-05

Phase 2

Progression-free Survival After MWA Plus Durvalumab and Tremelimumab for Unresectable Locally Advanced Pancreatic Cancer

CompletedNCT04156087

Baki TopalPancreatic Cancer Non-resectable

Start: 2020-05-09End: 2024-01-29Updated: 2024-09-19

RICE: Radio-Immuno-Chemotherapy of Cancer of the Esophagus

University of CologneEsophageal Adenocarcinoma

Start: 2019-09-30End: 2024-06-30Target: 56Updated: 2024-05-09

Adjuvant Chemotherapy and Immunotherapy for Completely Resected Small Cell Lung Cancer

RecruitingNCT07149363

Alliance Foundation Trials, LLC.Small Cell Lung Cancer (SCLC)

Start: 2026-02-12End: 2031-02-01Target: 65Updated: 2026-06-26

Related Papers

Perioperative durvalumab plus neoadjuvant chemoradiotherapy (CROSS) with and without tremelimumab in esophageal adenocarcinoma: The prospective phase II RICE trial (NCT04159974).

Journal of Clinical Oncology2026-05-27

Phase I/II study to evaluate consolidative hypofractionated radiation therapy for boosting the residual primary disease in combination with durvalumab after definitive chemoradiation therapy for stage III non-small cell lung cancer (NSCLC): study protocol for a prospective trial

Journal of Thoracic Disease2024-01-011 citations